IMforte: Maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small cell lung cancer (SCLC) vs atezolizumab alone.

DeLLphi-304: Phase 3 of tarlatamab vs chemotherapy for SCLC after progression on platinum-based therapy.

DeLLphi?303: Tarlatamab with first?line chemo?immunotherapy for ES?SCLC.

Welcoming delegates & dignitaries and Comparing the workshop

Past work, Hits & Misses, Going Forward

Navigating the patients and systems in cancer care

Geriatric Oncology Workshop

Loneliness and social isolation in older patients with cancer:

Chemotherapy related cognitive decline: Associated factors and management

Opening Remarks

Palliative Care Pathways Across the Lung Cancer Trajectory — From Diagnosis to Survivorship

Symptom Management Beyond Morphine — Updates in Pain and Symptom Science

· PL02.09 Aumolertinib plus Chemotherapy for NSCLC with EGFR and Concomitant Tumor Suppressor Gene (ACROSS 2): Phase III study

FLAURA2: Exploratory OS analysis—osimertinib + platinum-pemetrexed in poorer-prognosis EGFR-mutant NSCLC

Beamion LUNG-1 (Phase Ib): Zongertinib first-line in HER2-mutant NSCLC